Table 1.
Baseline patient characteristics.
| No relapse (n = 149) | CNS only recurrence (n = 24) | Systemic only recurrence (n = 43) | Concurrent recurrence (n = 10) | Pa | |
|---|---|---|---|---|---|
| Age, mean (SD), y | 62.5 ± 11.0 | 63.1 ± 12.7 | 63.3 ± 10.7 | 65.7 ± 7.0 | 0.830 |
| Male | 77 (52%) | 16 (67%) | 23 (54%) | 4 (40%) | 0.460 |
| Stage 3 or 4 | 137 (92%) | 23 (96%) | 43 (100%) | 10 (100%) | 0.420 |
| Elevated LDH | 133 (89%) | 21 (88%) | 39 (91%) | 10 (100%) | 0.714 |
| EN site ≥1 | 117 (79%) | 22 (92%) | 41 (95%) | 10 (100%) | 0.015 |
| EN site involvement | |||||
| Bone marrow | 52 (34.9%) | 16 (66.7%) | 17 (39.5%) | 6 (60%) | 0.016 |
| Kidney/adrenal | 37 (24.8%) | 10 (41.7%) | 7 (16.3%) | 4 (40%) | 0.096 |
| Testis | 1 (0.7%) | 1 (4.2%) | 1 (2.3%) | 3 (30%) | <0.001 |
| Breast | 1 (0.7%) | 2 (8.4%) | 1 (2.3%) | 0 (0%) | 0.065 |
| Double hit | 8 (5.3%) | 1 (4.2%) | 1 (2.3%) | 0 (0%) | 0.746 |
| Cell-of-origin (GCB) | 53 (36%) | 12 (50%) | 13 (30%) | 5 (50%) | 0.328 |
| CNS-IPI | |||||
| Low | 10 (6.7%) | 1 (4.2%) | 0 (0%) | 0 (0%) | 0.298 |
| Intermediate | 19 (12.8%) | 1 (4.2%) | 4 (9.3%) | 0 (0%) | |
| High | 120 (80.5%) | 22 (91.7%) | 39 (90.7%) | 10 (100%) | |
| IPI | |||||
| 1–2 | 26 (17.5%) | 22 (91.7%) | 42 (97.7%) | 0 (0%) | 0.061 |
| 3–5 | 123 (82.6%) | 2 (8.3%) | 1 ((4.2%) | 10 (100%) | |
| IT methotrexate | 27 (18.1%) | 4 (16.7%) | 5 (11.6%) | 3 (30%) | 0.537 |
| HDMTX | 53 (35.6%) | 2 (8.3%) | 10 (23.3%) | 1 (10%) | 0.015 |
Data are n (%), unless otherwise stated.
aClinical characteristics between the groups were compared using the χ2 test for categorical variables and one-way ANOVA for continuous variables. LDH lactate dehydrogenase, GCB germinal center B-cell like, EN extranodal, IT intrathecal, HDMTX high-dose methotrexate.